Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
142
-
Total 13F shares, excl. options
-
81.4M
-
Shares change
-
+9.18M
-
Total reported value, excl. options
-
$617M
-
Value change
-
+$70.5M
-
Put/Call ratio
-
0.57
-
Number of buys
-
72
-
Number of sells
-
-61
-
Price
-
$7.58
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2020
178 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2020.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.4M shares
of 236M outstanding shares and own 34.46% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (17.5M shares), Consonance Capital Management LP (7.12M shares), Nantahala Capital Management, LLC (6.56M shares), VANGUARD GROUP INC (5.89M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5.66M shares), STATE STREET CORP (3.42M shares), Novo Holdings A/S (3.39M shares), Point72 Asset Management, L.P. (1.97M shares), DIMENSIONAL FUND ADVISORS LP (1.84M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.82M shares).
This table shows the top 142 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.